Skip to main content
. 2016 May 26;7(25):38750–38761. doi: 10.18632/oncotarget.9606

Figure 3. Subgroup analyzes of 5-year survival.

Figure 3

A. Subgroup analysis of patients older than 65. There was a statistically significant difference (P=0.022). The 5-year survival rate was 64.1% for patients with Paf15-Low and 31.6% for patients with Paf15-High. B. Subgroup analysis of tumor size ≥15cm3. There was a statistically significant (P<0.001). The 5-year survival rate was 73.7% for patients with Paf15-Low and 33.3% for patients with Paf15-High.